Table 2.
Analysis of Biomarker Trajectories and Outcomes by Treatment Arm
| Hour 0 | Treatment Arm | Hour 6 | Stage 3 AKI, RRT, or Death within 7 d | |
|---|---|---|---|---|
| [TIMP-2] · [IGFBP7] > 0.3 (n = 457) | EGDT (n = 137) | [TIMP-2] · [IGFBP7] > 0.3 (n = 88, 64.3%) | 22/88 (25%) | 29 (21.1%) |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 49, 35.7%) | 7/49 (14.3%) | |||
| PSC (n = 158) | [TIMP-2] · [IGFBP7] > 0.3 (n = 101, 64.9%) | 23/101 (22.8%) | 28 (17.7%) | |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 57, 36%) | 5/57 (8.8%) | |||
| Usual care (n = 162) | [TIMP-2] · [IGFBP7] > 0.3 (n = 105, 64.8%) | 25/105 (23.8%) | 29 (17.9%) | |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 57, 35.2%) | 4/57 (7%) | |||
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 231) | EGDT (n = 83) | [TIMP-2] · [IGFBP7] > 0.3 (n = 26, 31.3%) | 8/26 (30.7%) | 12 (14.4%) |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 57, 68.7%) | 4/57 (7%) | |||
| PSC (n = 83) | [TIMP-2] · [IGFBP7] > 0.3 (n = 18, 21.6%) | 2/18 (11.1%) | 9 (10.8%) | |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 65, 78.4%) | 7/65 (10.7%) | |||
| Usual care (n = 65) | [TIMP-2] · [IGFBP7] > 0.3 (n = 11, 16.9%) | 2/11 (18.1%) | 6 (9.2%) | |
| [TIMP-2] · [IGFBP7] ≤ 0.3 (n = 54, 83.1%) | 4/54 (7.4%) | |||
Definition of abbreviations: AKI = acute kidney injury; EGDT = early goal-directed therapy; IGFBP7 = insulin-like growth factor–binding protein 7; PSC = protocol-based standard care; RRT = renal replacement therapy; TIMP-2 = tissue inhibitor of metalloproteinases-2.